Alerts
Personalised Cancer Vaccines Show Longer-Term Staying Power
Five-year data for intismeran autogene plus pembrolizumab strengthen the case for individualized neoantigen therapy in high-risk resected melanoma.
China’s PD-1/VEGF Bet Challenges the Lung Cancer Backbone
High-Risk Prostate Cancer Moves Before the Metastatic Clock Starts
Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority
Lenacapavir Turns HIV Prevention Into an Access Stress Test
WHO’s New AMR Plan Makes Stewardship and Access a Single Test
Can cortisol become the next target in type 2 diabetes?
An ADC Steps Into the First-Line Gap in Triple-Negative Breast Cancer
Alpha Radioligand Therapy Moves Prostate Cancer Into a New Infrastructure Test
Ebola PHEIC Turns Outbreak Control Into a Preparedness Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.